学习经历

2001-2005 南阳师范学院 生物系, 生命科学专业, 学士

2005-2008 首都师范大学 生命科学学院, 生物化学与分子生物学专业, 硕士

2008-2012 北京大学 生命科学学院, 生物化学与分子生物学专业, 博士

工作经历与任职

2012-2013 中国科学院微生物研究所, 助理研究员

2013-2015 美国哈佛医学院, Beth Deaconess Medical Center, 博士后

2015-2018 美国哈佛医学院/哈佛牙医学院, 讲师（Instructor）

2019-至今 武汉大学医学研究院, 教授

研究方向

新型免疫治疗靶点的发掘、治疗性抗体以及CAR T产品的研发

获奖与荣誉

国家海外引进高层次人才青年项目（2019）

代表性论文

1. Li HO^#, Sun YS^#, Yao YM^#, Ke SW, Zhang NN, Xiong WJ, Shi J, He C, Xiao XL, Yu HS, Dai PP, Xiang BL, Xing XX, Xu GS, Song WJ, Song JQ, Zhang JF^* (2024). USP8-governed GPX4 homeostasis orchestrates ferroptosis and cancer immunotherapy. PNAS: doi.org/10.1073/pnas.2315541121.

2. He C^#, Xing XX^#, Chen HY, Gao ML, Shi J, Xiang BL, Xiao XL, Sun YS, Yu HS, Xu GS, Yao YM, Xie ZS, Xing YJ, Budiarto BR, Chen SY, Gao Y, Lee YR^*, Zhang JF^* (2024). UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. Molecular Cell 84: 1-19.

3. Xiao XL^#, Shi J^#, He C^#, Bu X, Sun YS, Gao ML, Xiang BL, Xiong WJ, Dai PP, Mao Q, Xing XX, Yao YM, Yu HS, Xu GS, Li SQ, Ren Y, Chen BX, Jiang CQ, Meng G, Lee YR, Wei WY, Freeman GJ, Xie CH^*, Zhang JF^* (2023). ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nature Communications 14(1): 2859.

4. Yu HS^#, Liu J^#, Bu X^#, Ma ZQ^#, Yao YM, Li JF, Zhang TT, Song WJ, Xiao XL, Sun YS, Xiong WJ, Shi J, Dai PP, Xiang BL, Duan HT, Yan XL, Wu F, Zhang WC, Lin DD, Hu HK, Zhang HJ, Slack FJ, He HH, Freeman GJ^*, Wei WY^*, Zhang JF^* (2023). Cell Chem Biol 31: 1-16.

5. Xiong WJ^#, Gao XL^#, Zhang TT, Jiang BS, Hu MM, Bu X, Gao Y, Zhang LZ, Xiao BL, He C, Sun YS, Li HO, Shi J, Xiao XL, Xiang BL, Xie CH, Chen G, Zhang HJ, Wei WY, Freeman GJ, Shu HB, Wang HZ^*, Zhang JF^* (2022). USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nature Communications 13(1):1700.

6. Xiong WJ^#, Gao Y^#, Wei WY^*, Zhang JF^* (2021). Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends in Cancer 7(9):837-846.

7. Zhang NN^#, Gao YP^#, Huang ZR, Dai PP, Luo Y, Wu QJ, Jiang XP, Sun WJ, Zhang JG, Han L, Zhang JF^*, Gong Y^*, Xie CH^* (2023). PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy. Cancer Letters 545:(215852):1-12.

8. Zhang JF^#, Bu X^#, Wang HZ^#, Zhu YS, Geng Y, Nihira NT, Tan YY, Ci YP, Wu F, Dai XP, Guo JP, Huang YH, Fan CQ, Ren SC, Sun YH, Freeman GJ^*, Sicinski P^*, Wei WY^* (2018). Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553(7686):91-95.

9. Zhang JF^#, Lee YR^#, Dang FB^#, Gan WJ, Menon AV, Katon JM, Hsu CH, Asara JM, Tibarewal P, Leslie NR, Shi Y, Pandolfi PP^*, Wei WY^* (2019). PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage. Cancer Discovery (9):1306-1323.

10. Zhang JF^#, Chen M^#, Zhu YS^#, Dai XP, Dang FB, Ren JM, Ren SC, Shulga YV, Beca F, Gan WJ, Wu F, Lin YM, Zhou XB, DeCaprio JA, Beck AH, Lu KP, Huang J, Zhao C, Sun YH, Gao X^*, Pandolfi PP^*, Wei WY^* (2019). SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. Developmental Cell 48(3):329-344.e5.

11. Wan LX^#, Xu KX^#, Wei YK^#, Zhang JF^#, Han T, Fry C, Zhang Z, Wang YV, Huang LY, Yuan M, Xia WY, Chang WC, Huang WC, Liu CL, Chang YC, Liu JS, Wu Y, Jin VX, Dai XP, Guo JF, Liu J, Jiang SL, Li J, Asara JM, Brown M^*, Hung MC^*, Wei WY^* (2018). Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Molecular Cell 69(2):279-291.

12. Zhang JF^#, Dang F^#, Ren J, Wei WY^* (2018). Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends Biochem Sci 43(12)：1014-1032.